TY  - GEN
AU  - Xu,Peng-Peng
AU  - Fu,Di
AU  - Li,Jian-Yong
AU  - Hu,Jian-Da
AU  - Wang,Xin
AU  - Zhou,Jian-Feng
AU  - Yu,Hao
AU  - Zhao,Xia
AU  - Huang,Yao-Hui
AU  - Jiang,Lu
AU  - Liu,Feng
AU  - Su,Li-Ping
AU  - Chen,Zhuo-Wen
AU  - Zeng,Qing-Shu
AU  - Chen,Jie-Ping
AU  - Fang,Mei-Yun
AU  - Ma,Jun
AU  - Liu,Ting
AU  - Song,Yong-Ping
AU  - Yu,Kang
AU  - Li,Yan
AU  - Qiu,Lu-Gui
AU  - Chen,Xie-Qun
AU  - Gu,Jian
AU  - Yan,Jin-Song
AU  - Hou,Ming
AU  - Huang,Heng-Ye
AU  - Wang,Li
AU  - Cheng,Shu
AU  - Shen,Yang
AU  - Xiong,Hui
AU  - Chen,Sai-Juan
AU  - Zhao,Wei-Li
TI  - Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
SN  - 2352-3026
PY  - 2019///1030
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Anthracyclines
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Cyclophosphamide
KW  - Female
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Grading
KW  - Neutropenia
KW  - etiology
KW  - Proportional Hazards Models
KW  - Rituximab
KW  - Survival Rate
KW  - Treatment Outcome
KW  - Vincristine
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/S2352-3026(19)30051-1
ER  -